title: Titanium-nitride-oxIde-coated stents multicenter registry in diaBEtic patienTs: the TIBET registry.
abstract: We sought to explore the immediate clinical and angiographic results of the Titan(®) stent implantation in diabetic patients, as well as the major adverse cardiac events (MACE) at 6-month follow-up. We enrolled 156 consecutive diabetic patients admitted to undergo percutaneous intervention for at least one significant (50%) coronary lesion. All lesions were treated with the Titan(®) stent implantation according to the contemporary interventional techniques. Patients were prospectively followed-up for at least 6 months. The primary endpoint was MACE at 6-month follow-up [cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR)]. Secondary endpoints included angiographic and clinical procedural success, in-hospital MACE, TLR at 6-month follow-up, and stent thrombosis. The mean age was 66.7 ± 9.6 years, (68.4% males). A total of 197 Titan(®) stents were implanted in 163 lesions. Direct stenting was performed in 45.2% of the cases. The mean stent diameter was 3.1 ± 0.61 mm, and the mean length was 18.0 ± 8.9 mm. Average stent deployment pressure was 13.9 ± 4.2 bars. Angiographic procedural success was achieved in 154 (98.7%) cases, and clinical procedural success was achieved in 153 (98.1%) cases. One patient developed in-hospital non-Q-wave MI following the procedure. Clinical follow-up was completed in 155 (99.4%) patients. Three patients (1.9%) died of a cardiac or unknown cause, and two (1.3%) developed MI. TLR was performed in 11 patients (7.1%). Cumulative MACE at 6-month follow-up occurred in 16 (10.3%) patients. No patient suffered stent thrombosis. Titan(®) stent implantation in diabetic patients achieves an excellent immediate clinical and angiographic outcome, with a low incidence of MACE at mid-term follow-up.
authors: Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
authors: Mariano
authors: M
authors: Valdés Chavarri
authors: Mariano Valdés
authors: MV
authors: Chavarri
authors: Armando
authors: A
authors: Bethencourt
authors: Eduardo
authors: E
authors: Pinar
authors: Alfredo
authors: A
authors: Gomez
authors: Javier Fernández
authors: JF
authors: Portales
authors: Francisco
authors: F
authors: Pomar
authors: Isabel
authors: I
authors: Calvo
authors: Jose  Ramón
authors: J
authors: López-Minguez
authors: Jose Ramón López
authors: JR
authors: Minguez
authors: Raúl
authors: R
authors: Valdesuso
authors: José
authors: J
authors: Moreu
authors: Antonio
authors: A
authors: Martínez
authors: Wail
authors: W
authors: Nammas
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D003925:Diabetic Angiopathies / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control; D011446:Prospective Studies; D011474:Prosthesis Design; D012042:Registries; D013030:Spain / Q000453:epidemiology; D015607:Stents; D013927:Thrombosis / Q000401:mortality; D013997:Time Factors; D014025:Titanium; D016896:Treatment Outcome
chemical_list: D020099:Coated Materials, Biocompatible; C434243:titanium-nitride-oxide; D014025:Titanium